The MOMENTUM 3 trial compares the centrifugal HeartMate 3 (HM3) with the axial HeartMate II (HMII) continuous-flow left ventricular assist system in patients with advanced heart failure, irrespective of the intended goal of therapy. The trial's 2-year clinical outcome (n=366) demonstrated superiority of the HM3 for the primary end point (survival free of a disabling stroke or reoperation to replace or remove a malfunctioning pump). This analysis evaluates health resource use and cost implications of the observed differences between the 2 devices while patients were enrolled in the trial.
L
eft ventricular assist systems (LVASs) are increasingly adopted in the management of patients with advanced heart failure, but scaling their use across broader populations and geographic regions has been limited by 2 distinct factors. 1 First, although continuous-flow LVASs have now become commonly used in situations of bridge to transplantation, and destination therapy, wider dissemination is often curtailed by clinical concerns related to the aggregate burden of hemocompatibility-related adverse events such as strokes, bleeding, infection, and pump thrombosis, a dreaded complication that often requires pump exchange. 2, 3 Second, not only is the initial decision to implant a pump associated with considerable cost to the healthcare system, but the subsequent postimplant management of adverse events and the antecedent need for aggressive and frequent hospital-based care adds a prominent layer of economic concern that serves to decrease the net cost-effectiveness of this otherwise valuable therapy. [4] [5] [6] [7] [8] The HeartMate 3 (HM3), a fully magnetically levitated LVAS, has demonstrated its clinical superiority in comparison with the axial flow HeartMate II (HMII) pump in the short term (at 6 months), and in the long term (at 2 years), in the pivotal MOMENTUM 3 trial. 9, 10 This study, a randomized comparative effectiveness investigation of these 2 pumps, reported that the HM3 LVAS was superior in meeting its primary end point of survival free of a disabling stroke or the need for reoperation to replace or remove a malfunctioning device (hazard ratio, 0.46; 95% confidence interval, 0.31-0.69 [P<0.001 for superiority]). 10 These benefits were driven by the absence of need for pump exchanges because of pump thrombosis and, importantly, a halving of overall stroke rates with the HM3 pump (hazard ratio, 0.47; 95% confidence interval, 0.27-0.84; P=0.02), suggesting greater hemocompatibility between the patient and the device interface with this LVAS. Whether these clinical findings also translate into benefits in the domain of medical resource use (principally adverse event-driven hospitalizations) and cost of care remains unknown.
The purpose of this resource use analysis is several-fold: (1) primarily, to compare and contrast rehospitalizations for device-attributable events (DAEs) and those unrelated events (non-DAE) between the HM3 and HMII LVASs, following the index implant hospitalization; (2) to assess the aggregate costs (based on payer reimbursements, either public or private insurer) of rehospitalizations encountered between the 2 device arms; and (3) to determine the relative cost differences between the HM3 and HMII LVAS subgroups, including study outcome (transplant, death, or ongoing on device), type of insurance (public or private payer), sex, or intended goal of therapy (bridge to transplantation or destination therapy).
METHODS
MOMENTUM 3 is a prospective, multicenter, randomized, nonblinded, pivotal clinical trial comparing the HM3 to the HMII LVAS in patients who have advanced-stage heart failure, and its design has been previously described in detail. 11 Eligible patients for the long-term component of the trial were randomly assigned 1:1 to receive either the HM3 or the HMII LVAS irrespective of whether the treatment goal was bridge to transplant or destination therapy (DT). The primary end point of the trial as assessed at 2 years was survival free of disabling stroke and reoperation to remove or replace a malfunctioning device. The trial includes an adaptive design with 3 prespecified analyses: the short-term primary end point assessment in 294 patients at 6 months; a long-term primary end point assessment in 366 patients at 2 years; and a full cohort analysis of the end point in 1028 randomly assigned patients, again at 2 years. The first 2 analyses have been reported, and the final analysis is expected to be reported in 2019. 9, 10 The trial also prespecified the collection of health resource use data by use of hospital billing information provided prospectively by centers. All patients (or their authorized representatives) provided written informed consent, and each institutional ethics review board approved the trial conduct. Predefined adverse events, readmissions to the hospital, device malfunctions, and reoperations were reported and adjudicated by an independent clinical events committee blinded to the randomization sequence. An independent data safety and monitoring board was responsible for the clinical safety data. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure and are within the independent purview of the publications and presentations committee of the trial.
Clinical Perspective
What Is New?
• This 2-year analysis of the long-term MOMENTUM 3 trial compares the HeartMate 3 with the HeartMate II pump and demonstrates that the HeartMate 3 pump is associated with a significant reduction in rehospitalization and hospital days used.
• Overall costs following discharge were 51% lower with the HeartMate 3 than with HeartMate II pump, driven largely by a decrease in device-attributable events.
• Lower costs with HeartMate 3 were seen irrespective of intended goal of therapy (bridge to transplant or destination therapy).
What Are the Clinical Implications?
• The clinical superiority of the HeartMate 3 cardiac pump is associated with a lower cost of rehospitalizations at 2 years of follow-up after implantation.
• These findings in advanced heart failure suggest enhanced cost-effectiveness of left ventricular assist systems and may allow for more widespread use across different healthcare systems and geographic regions.
Circulation. 
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On April 6, 2018, the sponsor, Abbott, issued a Field Safety Notice, which was updated on May 21, 2018, regarding the HM3 Left Ventricular Assist System and reports of outflow graft twist complications occurring with an incidence rate of 0.72%. Outflow graft twist is a known complication after HM3 placement, and was previously reported in the pivotal trial. 10 The Food and Drug Administration terminology for a Field Safety Corrective Action is Recall, which was issued as a Class I Recall (reasonable probability that the use of, or exposure to a product can cause serious adverse health consequences or death). The Food and Drug Administration did not recommend the return of products or avoidance of using the product with new patients. The analyses presented in this article reflect attribution of twist events occurring during follow-up in the HM3 arm. We re-reviewed 20 hospitalizations (5 in the HM3 arm and 15 in the HMII arm) as possible device-related malfunction (eg, low-flow alarms, peripheral controller component malfunction) and in a conservative analysis classified them as being device-related for the purpose of this analysis.
Economic Resource Analyses
The specific methodology for the economic medical resource use and cost analysis is described below.
Hospitalization Resource Use Methodology
Healthcare utilization data were collected concurrently during the trial. The Universal Billing form UB-04 (form CMS 1450) was collected specifically for inpatient hospitalizations that occurred in the study patients. This is a standard form used by institutions in the United States to bill insurance providers for medical services provided to the patients. The UB-04 form fields include admission date, discharge date, type of admission, type of insurance, admitting diagnosis code, all diagnoses codes, and all procedure codes.
Cohort and Event Derivation
There are important differences between the resource use and cost analysis and the original clinical analysis of the trial cohort. The primary cost analysis mainly considers nonindex rehospitalizations. This was specified by design because all index hospitalizations cover the same procedure (implantation of a LVAS), and the costs of devices used were identical within the trial. Therefore, other than outlier costs (unexpected adverse events), we expect little variation (addressed in secondary cost analyses in Results). Of the 366 randomly assigned patients, 361 received the intended implant device (5 were randomly assigned and did not undergo implantation), and 12 patients in each arm were not discharged because of death or study censoring (CONSORT diagram, Figure 1 ). Furthermore, unlike the primary end point clinical analysis that did not report patient outcomes after reaching a pump exchange event, we report healthcare resource data for subsequent adverse events and rehospitalizations in this analysis. Other censoring events (ie, study withdrawal, heart transplantation, explant, pump exchange with a nonstudy device, and death) remain the same in the resource use and the clinical analysis. Our primary analysis, therefore, includes rehospitalizations after the index hospitalization and before the patient was censored. In addition, we conducted secondary analyses by using estimates of index hospitalization costs and compensated for censoring by applying average event costs (for heart transplant and death) derived from the literature. 7 We also conducted subgroup analyses of withintrial costs for subjects who died during the trial, subjects who received a transplant, and subjects who remained on HeartMate support at 2 years of follow-up.
Cost Estimates of Hospitalizations
Costs in this study were assessed from the payer perspective and are equivalent to the reimbursement hospitals receive for each related event (in US dollars adjusted to 2017 figures). Each hospitalization was associated with a clinical adjudication (determined by the clinical study adjudication committee) and a specific reimbursement, estimated by using a combination of trial data and payer administrative claims databases. Because of variation in study site institutional review board rules and compliance, only a subset of hospitalizations had codes available to allow for diagnosis related group (DRG) grouping. For hospitalizations where UB-04 forms containing admission and procedure codes were available, the hospitalizations were assigned to an appropriate DRG using the MS-DRG Grouper, Calculator & Analyzer software available on the MediRegs platform from Wolters Kluwer. 12 The DRG code was then used to identify average reimbursement related to the DRGs within administrative claims. Specifically, the average costs for Medicare insurance claims were calculated from the Medicare Limited Data Set that contained deidentified Medicare claims for the first 9 months of 2017, 13 and average costs for private commercial insurers were calculated from the Marketscan Commercial Claims database (which contains a nationally representative sample of commercial insurance payments for 2016, converted to 2017 dollars using the Medical Consumer Price Index).
14,15

Ascertainment of Insurance Plan
The insurance plan attributable to each patient was determined using the Primary Payer field in the UB-04 forms where available, and, where not available, the insurance type was assigned based on the age of the patient: age ≥65 years assigned to Medicare insurance, and age <65 years assigned to private insurance. Making the distinction between patients who were insured by the public payer (Medicare) and those who were insured commercially was important in this analysis, because reimbursement from commercial insurance is often much higher than Medicare (usually by a factor of 2-fold higher for the private payer).
Assessment of Reimbursement for Hospitalizations
For those hospitalizations that could not be assigned to a DRG, costs were determined by the use of regression modeling. We developed regression models to predict hospitalization cost as a function of patient and hospitalization characteristics. The average reimbursement for the assigned DRG was regressed on actual adverse events related to the hospitalization (ie, pump replacement, arterial non-central nervous system thromboembolism, cardiac arrhythmia, hemolysis, hepatic dysfunction, major bleeding, major infection, neurological dysfunction, pericardial fluid, psychological episode, renal dysfunction, respiratory failure, right heart failure, venous thromboembolism, and myocardial infarction), the number of days in intensive care, the length of stay, and the patient's age.
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Four different functional forms of the regression were considered (Gaussian, Gamma, Gaussian with a log link/transformation of cost, and Gamma with a log link/transformation of cost) and 2 variable selection approaches (backward stepwise regression with P<0.20 and least absolute shrinkage and selection operator [LASSO]) were used to develop 6 candidate models. The Gamma family is desirable because it is defined over a nonnegative support (predicted costs will always be nonnegative) and is right-skewed, which is a good fit for medical cost data where a few values can represent high outliers. The Gaussian family is desirable because parameters are easy to interpret; however, because support is over the real number line, predicted costs could theoretically be negative. A log transformation on the cost data may lessen the impact of heterogeneity on the model (ie, if variance is increasing with cost, a log transformation will smooth out the variance in the regression).
To choose an appropriate model, all models were estimated by using the available observations. For each model specification, independent variables were selected using backward stepwise regression with a cutoff threshold of P≤0.20 (P values were based on the analytically derived P values, not bootstrap P values). In addition, a LASSO regression approach was applied to the Gaussian families. Separate regressions were estimated for each model specification, using both the Medicare average reimbursement by UB-04 form-assigned DRG and the Marketscan Commercial average reimbursement by DRG. A generalized linear model (GLM) regression was used for models selected with backward regression, and an ordinary least-squares approach was used for models selected with LASSO. Results are shown in Tables I and II in the online-only Data Supplement.
Goodness of fit was assessed graphically, with deviance, and with residual mean square error. Histograms of deviance residuals for the different models were constructed (Figures I through IV in the online-only Data Supplement). For a correctly specified model, the histogram should be approximately normally distributed. 16 This plot suggests that the Gaussian model without the log link is not a good fit for our data given the large dispersion of the residuals ( Figure III in the online-only Data Supplement).
Although deviance is an established method of assessing model fit, deviance is not generally comparable between families. Nevertheless, it can be useful in deciding if the log transformation within a family produces a better fit. In the Gamma and Gaussian models selected with backward selection, deviance was lower for estimation with the log link function than with the identity link. In contrast, the LASSO had greater deviance using the log transformation than using untransformed data. The Gaussian models estimated with backward stepwise regression had lower deviance than the LASSO models.
A lower root mean square error is 1 measure of a better model fit. Root mean square error was lowest in the Gaussian GLM estimation with log link (6980) and highest in the Gamma GLM regression with log link (11 827). In the Gaussian GLM regressions, root mean square error is lower with the log link function than with the identity link, whereas the opposite is true in the Gamma GLM regressions.
No regression model was clearly dominant in the goodness-of-fit assessments. Given the nature of the cost data (right-skewed, strictly positive), Gamma regression was chosen. Among the Gamma regressions, the log-linked regressions have lower deviance, but higher root mean square error. Because of the highly skewed nature of the cost data, we selected the Gamma regression model with a log link as our baseline model. The sensitivity of this assumption is assessed in Table III in the online-only Data Supplement.
Once the regressions were estimated (using hospitalizations that could be assigned to DRG codes), the regression ORIGINAL RESEARCH ARTICLE equations were used to predict costs for hospitalizations that could not be assigned to a DRG. These costs were predicted based on the same parameters used in the regression estimation (ie, adverse events related to the hospitalization, number of days in intensive care, length of hospital stay, and patient age). Details on model parameterization, estimation, and diagnostics can be found in the online-only Data Supplement Statistical Appendix (Tables I through III and Figures I 
Statistical Analysis
We compared patient characteristics by treatment arm to verify that our arms remained balanced after excluding patients who left the study before index admission discharge. Patients were compared on demographic factors and clinical characteristics. Categorical variables were compared between the 2 treatment groups with the use of the Fisher exact test or χ 2 test, and continuous variables were compared with the unpaired t test or Wilcoxon rank-sum test as appropriate. Two-sided P values of <0.05 are considered to indicate statistical significance.
Medical resource use was quantified for all inpatient hospitalizations that occurred in each group over the study period. Hospitalizations were categorized based on the primary reason for readmission. Those occurring because of an adverse event adjudicated as suspected device thrombosis, stroke, driveline infection or sepsis, gastrointestinal bleeding, right heart failure, or a suspected device malfunction were defined as a DAE. We report the number of each rehospitalization type by treatment group and conduct the Pearson χ 2 test to determine if the proportions of hospitalization type are similar between groups. We also report mean cost per hospitalization by hospitalization type and treatment group. To estimate total hospitalization costs, hospital costs over 2 years were summed for each subject. Hospital admissions and total days in the hospital were also summed for each subject. To adjust for censoring, we primarily compared the cost per patient-year (subjects' total cumulative cost divided by their follow-up time in the study), the hospital days per patientyear (subjects' total hospital days divided by their follow-up time in the study), and total admissions per study year (subjects' total number of admissions divided by their follow-up time in the study) between treatment arms. Average costs are primarily shown with standard error. Median cost values with 90% confidence intervals are also provided in the supplement (Table IV in the online-only Data Supplement).
Because of the complexity associated with imputing cost data, standard statistical tests would be inappropriate to confirm statistical significance in cost between groups. Because HM3 was demonstrated to be superior with regard to the trial's long-term primary end point and adverse event rates were lower or similar in comparison with HMII, 1-tailed tests were used to determine if HM3 medical resource use was significantly lower than HMII medical resource use. One-tailed P values were estimated using nonparametric bootstrapping for comparisons within the primary group of discharged patients and patient subgroups. The bootstrap was conducted 1500 times to ensure consistent results, which is greater than the recommended minimum of 1000 replications. 17 We also conducted a variety of statistical tests to assess the sensitivity of our primary results to differing modeling approaches. We assessed how primary results varied for each of the 6 candidate models. To ensure that results were not driven by imbalance in insurance type between groups, we reran the analysis using Medicare reimbursement (and then commercial reimbursement) for all subjects. The analysis was also redone using only rehospitalizations that could be coded to a specific DRG. All analyses were conducted using STATA 13.1 (StataCorp LLC) or SAS 9.4 (SAS Institute).
RESULTS
Patient Cohort
The primary medical resource use and cost evaluation study population, consisting of those discharged fol- 
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lowing the initial implant hospitalization, included 337 patients (177 in the HM3 group and 160 in the HMII group) (CONSORT, Figure 1) . A comparison of baseline patient characteristics showed no significant differences in demographic and clinical factors between the 2 study groups (Table 1) .
Medical Resource Use
There were 537 total hospitalizations in the HM3 group and 501 hospitalizations in the HMII group. χ 2 Tests comparing the proportion of different hospitalization types (DAE and non-DAE) show fewer hospitalizations attributable to device-attributable adverse events in the HM3 group (P<0.001) ( Table 2 ). HM3 DAE rehospitalizations were significantly less expensive than HMII DAE hospitalizations (HM3: $21 780; HMII: $46 547; P<0.001) ( Table 2 ). Figure 2 shows the distribution of adverse events leading to a DAE readmission. In the HMII arm, a higher percentage of patients was hospitalized for pump thrombosis (HM3: 0.6% versus HMII: 12.5%; P<0.001) and stroke (HM3: 2.8% versus HMII: 11.3%; P=0.002). With respect to non-DAE hospitalizations, a comparison of cost per rehospitalization for each hospitalization type demonstrated no significant difference between the HM3 and HMII groups.
Primary Cost Analysis
The average cumulative cost per patient-year in those randomly assigned to HM3 was 50.8% lower than with the HMII ($37 685 in HM3 and $76 599 in HMII; P<0.001) ( Other reasons (non-DAE), n (%) 368 (69) 293 (58) 661 (64) Non-device-related local infection 42 (8) 41 (8) 83 (8) Cardiac arrhythmia 35 (7) 33 (7) 68 (7) Anticoagulation maintenance 46 (9) 15 (3) 61 (6) Pain and trauma 34 (6) 19 (4) 53 (5) Worsening heart failure and fluid overload 26 (5) 21 (4) 47 (5) Syncope/presyncope 24 (4) 18 (4) 42 (4) Nongastrointestinal bleeding 8 (1) 15 (3) 23 (2) Other complications † 134 (25) 121 (24) 255 (25) Scheduled testing/elective procedures 19 (4) 10 (2) 
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The treatment effect using conditional hospitalization (expected total cost of a patient at a given time, conditional on that patient still being in the trial) over time is captured in Figure 3 , which shows the cumulative cost at each point in time divided by the number of patients still enrolled in the trial.
Secondary Cost Analyses
In a secondary cost analysis, the entire patient population was considered insured through Medicare or private insurance (Table 4 ). All costs were higher when patients were modeled as having private insurance, and there was a significant cost savings of $81 568 per patient-year with HM3. The cost savings were smaller in magnitude but still significant ($30 648 per patient-year) if all patients were insured through Medicare.
The cost savings stratified by different subgroups (study outcome, intended goal of therapy, type of insurance, or sex) were also assessed ( Figure 4 ). For patients who died, there was a significant cost savings of $59 341 (P=0.021) and a similar trend in patients receiving a heart transplantation. In both DT and bridge to transplant subgroups, the average cumulative cost per patient-year is significantly less for HM3, with an average savings of $39 773 in patients assigned DT (P<0.001) and $38 989 for patients assigned bridge to transplant (P=0.020). The conditional costs over 2 years are shown for DT and bridge to transplant patients in Figure 5 .
To ensure that the exclusion of potential costs accrued during the index hospitalization, heart transplan-
Figure 2. Hospitalizations and proportional causes for device-attributable events.
More patients in the HeartMate II group were hospitalized because of pump thrombosis (P<0.001) and stroke (P=0.002) than patients in the HeartMate 3 group. DAE indicates device-attributable event; GI, gastrointestinal; and RHF, right heart failure. tation, or death would not cause directional bias in the overall cost assessment, we performed another secondary analysis of all patients in the long-term cohort. This analysis included index hospitalization costs and estimated costs for heart transplant and death with previously published data (Table V in the online-only Data Supplement). 7 With the inclusion of these additional costs, the average cumulative cost savings over the study period with HM3 was $65 602 (HM3: $473 774 versus HMII: $539 376; P=0.009).
Sensitivity Analyses for Cost Differences
We conducted a sensitivity analysis using only those hospitalizations that had allocated DRG codes available. Even with this limited analysis using only 31% of the hospitalizations, the average cost per study year is $9713 less for HM3 than for the HMII LVAS group (P=0.045). Other outcomes are similarly smaller in magnitude but consistent with the full analysis using imputed costs (reflecting the false-negative rate attributable to a considerably smaller sample size in the sensitivity analysis).
DISCUSSION
The findings of this investigation demonstrate that the long-term (2-year) clinical superiority demonstrated by the HM3 fully magnetically levitated centrifugal flow pump is also associated with fewer rehospitalizations and days spent in the hospital for clinically significant adverse events (predominantly because of DAEs including suspected pump thrombosis and stroke-related hospitalizations) following discharge from the index implant-related hospitalization. It is important to note that the total costs to payers (either public or private) ORIGINAL RESEARCH ARTICLE are significantly lower over the period of follow-up in those receiving the HM3 LVAS than in those undergoing implantation with the HMII pump. Healthcare transformation, driven by the rising costs of medical care, has necessitated a focus on cost-effectiveness encircling any technological advance with established clinical effectiveness. Historically, the earlygeneration pulsatile durable LVASs were deemed to not be cost-effective because they did not provide sufficient prolongation in quality-adjusted life-years. 18 Initially, costs were prohibitive based on economic metrics, but as management in the postimplant period began to improve and clinical outcomes were enhanced, the cost-effectiveness was enriched, yet not to thresholds accepted as viable within a society for unfettered access to such therapy. 19 The advent of miniaturized and more durable continuous-flow centrifugal or axial flow pumps heralded a new era in clinical effectiveness of durable LVASs, and as greater use and acceptance prompted application in large numbers, economic implications have become paramount. Analyses of advanced heart failure populations targeted as candidates for heart transplantation, and thereby use of LVASs as a bridge, have found affirmation in several countries that have deemed such a use to fall within acceptable cost-effectiveness ratios; however, use of this technology in transplant-ineligible patients (those considered as DT) has not received widespread endorsement. 20, 21 Using a Markov model in the context of a contemporary continuous-flow LVAS use, Rogers and colleagues 4 demonstrated that, in comparison with medically managed patients, these devices had an incremental costeffectiveness ratio of $198 184 per quality-adjusted life-year gained. It is important to note that they determined that the results were most sensitive to the initial cost of device implantation and subsequent cost per rehospitalization. In another analysis, Baras Shreibati and colleagues 5 examined the cost-effectiveness of left ventricular assist devices as DT in ambulatory patients with advanced heart failure. In their model, a value for incremental cost-effectiveness ratio of $209 400 per quality-adjusted life-year gained was noted in compari- 
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son with medical management. It is important to note that this study analyzed the sensitivity based on readmission rates and outpatient care costs. In this analysis, they found that the incremental cost-effectiveness ratio would drop to a threshold of $86 900 if postimplant costs could be reduced by $51 000 in tandem with a 50% lower readmission rate than those encountered with current devices, such as the axial-flow HMII pump. This would then reach a threshold at which the economic implications of using LVAS would become more palatable for wider use. Our investigation has demonstrated that the decrease in rehospitalizations and hospital days and the corresponding cost savings of 51% with the HM3 resulting from superior clinical effectiveness (in comparison with the HMII pump) may help us reach the point at which LVAS would be expected to become more cost-effective by meeting societal norms for willingness to pay for incremental benefit (which is now suggested to be an incremental cost-effectiveness ratio of $100 000-$150 000 in the United States). 22 In a secondary analysis, we included the costs attributable to the index hospitalization and also assigned an estimated value to censored events such as transplant episodes and deaths. This analysis, if confirmed using actual cost data, when we analyze the full cohort of the MOMENTUM 3 trial (in 1028 patients) once available, will point to the greater cost-effectiveness of the HM3 LVAS.
Whether these results from the United States could be scalable and applicable for interpretation across geographic boundaries remains an important issue. Healthcare systems across the world have different costs, societal thresholds for determining cost-effectiveness of therapy, and organization of funding for provision of care. Healthcare funding within the United States is unique because it represents a multipayer system and is often a mixture wherein patients shuttle between the public and private sectors. 23 In this context, the Medicare system, a public-funded enterprise for the elderly, would be similar in funding and scope to a country that supports a single-payer universal healthcare system such as the United Kingdom organized via its National Health Service. 24 However, some countries that support private insurance do so through taxation at the citizen or employer level but may mimic, in part, the commercial system in the United States. Such a healthcare system is prevalent in Germany, where one requires private insurance for high-end procedures and therapy (which typically supplements governmental basic funding). 24 In our data, the payer type, either Medicare or private payers, accrued similarly significant cost savings with the HM3, and the degree of relative cost reductions could be immediately translatable to either model of healthcare funding in other regions. In essence, we demonstrate that our data may have scalability and applicability within the framework of other payer systems, predominantly driven by the improved outcomes of the HM3 LVAS that drive the decrease in hospitalizations and their subsequent cost rather than reliance on processes of care or delivery models.
The clinical success of the HM3 LVAS, the reduction in adverse event profiles of stroke and need for a pump exchange, and the consequent decreases in readmission rates will lead to enhanced cost-effectiveness of such therapy. Yet, further progress is needed in enhancing the usefulness and application of the current generation of LVASs. In this regard, the clinical findings of a virtual absence of pump thrombosis-related complications has opened the door to consideration of reduced anticoagulation strategies or even consideration for elimination of such therapy. A pilot trial has shown the safety of lowintensity anticoagulation use with the HM3 pump in the short term at least to 6 months postimplantation. 25, 26 Although these early findings require confirmation in the context of larger-scale randomized trials, this important step ushers in the possibility that, if demonstrated to be safe, bleeding-related complications could be decreased, such as gastrointestinal bleeds, and hemorrhagic strokes, as well. If this is proven, the technology will become even more cost-effective in the future. One area that remains challenging relates to the presence of exit-site drive-line infections attributable to the need to externally power the LVAS. A fully internalized driveline and elimination of infection carries the promise of a greater quality of life for the patient and a further reduction in overall costs of care.
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Limitations
The primary study analysis does not include the index hospitalization costs because they were deemed to be similar between the devices; however, they do not account for the outlier costs. In our secondary analysis where we included costs accrued during the index hospitalization, and censored events such as heart transplant or death, as well, the difference in cost was only further magnified in favor of the HM3, driven again by the early need for device exchange and stroke rates in the HMII group. There were proportionally similar numbers of patients leading to the inability to discharge (6.3% in the HM3 group versus 7.0% in the HMII group) and numerically more patients discharged in the HM3 group that would have allowed for a greater number of patients available to add cost to this group. Yet, the reduced rate of adverse events noted with the HM3 contributed significant cost savings despite this apparent disadvantage. Similarly, outpatient costs occurring over the study period, although not believed to be comparatively significant (dressing changes, battery exchanges, routine visits for device interrogation, and diagnostic testing), were not captured in this analysis. It is important to underscore that the largest share of overall costs, regard-less of technology, is related to the index hospitalization (acquisition cost of the device), but the greatest magnitude of difference in costs accrues from the postimplant follow-up phase. One other limitation is that costs were assessed using a hybrid model (the actual DRG codes in those available [31% of all hospitalizations] and in others a regression model based on the actual events related to hospitalization). We emphasize that the cost regression modeling took into account the actual costs incurred by various adverse effects, adjusted for patient demographics, and demonstrated a high precision and fidelity on testing. The analyses that include heart transplants and deaths used estimated, not actual costs, and must be considered in this context as more general findings. In principle, because rates of heart transplantation and deaths were numerically greater in the HMII arm, this would have only magnified the cost differences noted between the devices.
CONCLUSIONS
In this medical resource use (hospitalization-based) and corresponding cost analysis of the outcomes in the MO-MENTUM 3 trial at 2 years, the HM3 demonstrated a reduction in rehospitalization-related hospital days and a significant cost savings in comparison with the HMII LVAS. These cost savings with the HM3 were independent of payer type, whether public or private insurance, and are also seen across different subgroups, including those intended for bridge to transplantation or destination therapy. These important findings suggest that the clinical benefits of the HM3 pump decrease the cost of care while growing the health utility over time, allowing for a relative cost-utility benefit for this therapeutic modality.
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